Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor
- 28 December 2020
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 269, 120635
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 85 references indexed in Scilit:
- Targeting PD-1/PD-L1 interactions for cancer immunotherapyOncoImmunology, 2012
- Quantitative structure - property relationship modeling of remote liposome loading of drugsJournal of Controlled Release, 2012
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II TrialJournal of Clinical Oncology, 2011
- GSK-3 Inhibitors: Preclinical and Clinical Focus on CNSFrontiers in Molecular Neuroscience, 2011
- Stromal biology and therapy in pancreatic cancerGut, 2010
- Relationship between CD107a expression and cytotoxic activityCellular Immunology, 2009
- Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam1−/− miceOncogene, 2008
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005
- Antibody Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2004
- Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re‐filling of the lytic granules and secretion of lytic proteins via a non‐granule pathwayEuropean Journal of Immunology, 1995